MIS plans to produce radiopharmaceuticals in U.K.
Molecular Imaging Services has signed an agreement to establish a commercial radiopharmaceutical production unit at Keele University Science Park in Staffordshire, U.K. The unit will produce PET radiopharmaceuticals. MIS was established in 2002 as a
Molecular Imaging Services has signed an agreement to establish a commercial radiopharmaceutical production unit at Keele University Science Park in Staffordshire, U.K. The unit will produce PET radiopharmaceuticals. MIS was established in 2002 as a joint venture between Phoenix-based Alliance Medical and Dublin-based M2i. Its primary goal is to establish a number of such production units to support the expanded use of PET in the U.K.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
